Rybelsus, which works like Novo’s Ozempic and Lilly’s Trulicity, gained FDA approval in 2019 as a daily oral alternative to those two drugs, which require weekly injections. However, that initial OK was accompanied by a recommendation doctors not prescribe Rybelsus as a first-line treatment for people with diabetes who are unable to control their blood sugar levels with diet and exercise alone. Merck’s Januvia and Lilly’s Jardiance, by comparison, already held approvals for that use.
“By taking Rybelsus first, people with Type 2 diabetes, in conjunction with their care teams, are now able to utilize this medicine early in their diabetes treatment journeys,” Aaron King, a family medicine and diabetes specialist in San Antonio, Texas said in a statement from Novo Nordisk.
Rybelsus has the same active ingredient as Ozempic, but at a higher dosage and modified to aid its absorption in the stomach.
The new use for Rybelsus comes as diabetes drug competition is intensifying. In the class of drugs called GLP-1 agonists, Rybelsus is the only oral treatment, but must be taken daily, while the latest injectable drugs can be taken once a week. READ MORE
By Jonathan Gardner
As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.
McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.
AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.